Malka, D., François, E., Penault-Llorca, F., Castan, F., Bouché, O., Bennouna, J., Ghiringhelli, F., de la Fouchardière, C., Borg, C., Samalin, E., Bachet, J., Raoul, J., Miglianico, L., Bengrine-Lefèvre, L., Dahan, L., Lecaille, C., Aparicio, T., Stanbury, T., Perrier, H., Cayre, A., Laurent-Puig, P., Gourgou, S., Emile, J., & Taïeb, J. (2019). fOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. European journal of cancer, 115, 97–106. http://access.bl.uk/ark:/81055/vdc_100086215718.0x000037